| Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Raising the bar for lower-risk myelodysplastic syndromes |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Advances in the management of higher-risk myelodysplastic syndromes: future prospects |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Eat and be healthy: nutritional status in myelodysplastic syndromes |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience |
|
Leukemia & Lymphoma |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Clonal dynamics of aplastic anemia/paroxysmal nocturnal hemoglobinuria |
|
Leukemia & Lymphoma |
Aplastic Anemia |
